ACHC · Acadia Healthcare Company, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $828.80M | - | $851.57M | $869.23M | $770.50M | - | $815.63M | $796.04M | $768.05M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - |
| Total Operating Expenses | $817.84M | - | $811.59M | $819.23M | $757.04M | - | $717.07M | $689.58M | $669.21M | - |
| D&A | $52.43M | - | $47.47M | $48.99M | $47.03M | - | $37.64M | $36.07M | $36.35M | - |
| Operating Income | $10.96M | - | $39.98M | $50.00M | $13.47M | - | $98.57M | $106.46M | $98.84M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $6.50M | - | $1.67M | $12.07M | $4.40M | - | $27.20M | $25.64M | $20.07M | - |
| Net Income | ($1.18B) | - | $36.25M | $30.13M | $32.62M | - | $68.13M | $78.48M | $57.73M | - |
| EPS - Basic | $0.05 | - | $0.40 | $0.33 | $0.09 | - | $0.74 | $0.86 | $0.84 | - |
| EPS - Diluted | $0.05 | - | $0.40 | $0.33 | $0.09 | - | $0.74 | $0.85 | $0.83 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $158.47M | $133.24M | $118.69M | $131.42M | $91.24M | $76.31M | $82.14M | $77.17M | $77.30M | $100.07M |
| Accounts Receivable | $471.75M | $440.60M | $430.84M | $408.54M | $396.63M | $365.34M | $383.94M | $389.37M | $386.19M | $361.45M |
| Inventory | $5.93M | $5.69M | $6.25M | $5.82M | $5.71M | $5.65M | $5.51M | $5.99M | $5.75M | $5.30M |
| Accounts Payable | $142.20M | $150.40M | $179.94M | $219.82M | $204.01M | $232.70M | $201.38M | $159.52M | $156.13M | $156.13M |
| Current Assets | $837.20M | $814.14M | $747.96M | $691.56M | $638.95M | $577.49M | $652.06M | $645.21M | $610.81M | $596.00M |
| Total Assets | $5.55B | $5.53B | $6.41B | $6.31B | $6.15B | $5.96B | $5.87B | $5.68B | $5.52B | $5.36B |
| Current Liabilities | $489.36M | $525.19M | $517.92M | $523.71M | $473.35M | $577.92M | $609.50M | $546.52M | $482.31M | $885.78M |
| Long-term Debt | $2.49B | $2.47B | $2.28B | $2.25B | $2.18B | $1.88B | $1.80B | $1.77B | $1.79B | $1.34B |
| Total Liabilities | $3.38B | $3.39B | $3.12B | $3.08B | $2.97B | $2.77B | $2.72B | $2.61B | $2.54B | $2.47B |
| Stockholders' Equity | $1.96B | $1.95B | $3.12B | $3.08B | $3.04B | $3.07B | $3.03B | $2.95B | $2.87B | $2.78B |
| Retained Earnings | ($761.74M) | ($765.84M) | $411.67M | $375.42M | $348.45M | $387.33M | $354.72M | $286.59M | $208.10M | $131.72M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $61.53M | - | - | - | $11.48M | - | - | - | ($321.29M) | - |
| Investing Cash Flow | ($60.21M) | - | - | - | ($183.24M) | - | - | - | ($184.61M) | - |
| Financing Cash Flow | $23.91M | - | - | - | $186.69M | - | - | - | $483.13M | - |
| CapEx | $76.56M | - | - | - | $174.63M | - | - | - | $142.41M | - |
| Free Cash Flow | ($15.03M) | - | - | - | ($163.15M) | - | - | - | ($463.69M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 1.3% | - | 4.7% | 5.8% | 1.7% | - | 12.1% | 13.4% | 12.9% | - |
| EBITDA margin | 7.6% | - | 10.3% | 11.4% | 7.9% | - | 16.7% | 17.9% | 17.6% | - |
| Net margin | -142.1% | - | 4.3% | 3.5% | 4.2% | - | 8.4% | 9.9% | 7.5% | - |
| Free cash flow margin | -1.8% | - | - | - | -21.2% | - | - | - | -60.4% | - |
| FCF / Net income | 0.01 | - | - | - | -5.00 | - | - | - | -8.03 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | 4.4% | 28.6% | 11.9% | - | 28.5% | 24.6% | 25.8% | - |
| Return on assets | -21.2% | - | 0.6% | 0.5% | 0.5% | - | 1.2% | 1.4% | 1.0% | - |
| Return on equity | -60.1% | - | 1.2% | 1.0% | 1.1% | - | 2.2% | 2.7% | 2.0% | - |
| Return on invested capital | 0.2% | - | 0.7% | 0.7% | 0.2% | - | 1.5% | 1.7% | 1.6% | - |
| Liquidity | ||||||||||
| Current ratio | 1.71 | 1.55 | 1.44 | 1.32 | 1.35 | 1.00 | 1.07 | 1.18 | 1.27 | 0.67 |
| Quick ratio | 1.70 | 1.54 | 1.43 | 1.31 | 1.34 | 0.99 | 1.06 | 1.17 | 1.25 | 0.67 |
| Cash ratio | 0.32 | 0.25 | 0.23 | 0.25 | 0.19 | 0.13 | 0.13 | 0.14 | 0.16 | 0.11 |
| Leverage | ||||||||||
| Debt / Equity | 1.27 | 1.27 | 0.73 | 0.73 | 0.72 | 0.61 | 0.60 | 0.60 | 0.63 | 0.48 |
| Debt / Assets | 0.45 | 0.45 | 0.36 | 0.36 | 0.36 | 0.32 | 0.31 | 0.31 | 0.33 | 0.25 |
| Debt / EBITDA | 39.35 | - | 26.13 | 22.70 | 36.10 | - | 13.25 | 12.45 | 13.27 | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.83 | 2.84 | 2.06 | 2.05 | 2.02 | 1.94 | 1.94 | 1.92 | 1.93 | 1.93 |
| Liabilities / Assets | 0.61 | 0.61 | 0.49 | 0.49 | 0.48 | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 |
| Efficiency | ||||||||||
| Asset turnover | 0.15 | - | 0.13 | 0.14 | 0.13 | - | 0.14 | 0.14 | 0.14 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 208d | - | 185d | 172d | 188d | - | 172d | 179d | 184d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 467.8x | - | 61.9x | 68.8x | 336.9x | - | 85.7x | 79.5x | 95.4x | - |
| P / B | 1.1x | - | 0.7x | 0.7x | 0.9x | - | 1.9x | 2.1x | 2.5x | - |
| P / S | 2.6x | - | 2.6x | 2.4x | 3.6x | - | 7.2x | 7.8x | 9.5x | - |
| EV / EBITDA | 70.4x | - | 50.4x | 42.1x | 80.7x | - | 55.6x | 55.5x | 66.6x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 7.6% | - | 4.4% | 9.2% | 0.3% | - | 8.7% | 8.8% | 9.1% | - |
| Revenue CAGR (3y) | 5.6% | - | 8.5% | 10.1% | 7.7% | - | 11.6% | 11.0% | 11.7% | - |
| Revenue CAGR (5y) | 8.5% | - | 0.4% | 3.0% | -0.3% | - | 1.0% | 0.2% | 0.2% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -18.6% | - | -59.4% | -53.0% | -86.4% | - | - | 10.4% | 15.4% | - |
| Net income growth (YoY) | - | - | -46.8% | -61.6% | -43.5% | - | - | 8.6% | -5.6% | - |
| EPS growth (YoY) | -44.4% | - | -45.9% | -61.2% | -89.2% | - | - | 7.6% | 15.3% | - |
| EPS CAGR (3y) | -58.9% | - | -20.0% | -27.9% | -48.8% | - | 0.5% | 20.2% | 96.1% | - |
| EPS CAGR (5y) | -14.6% | - | -1.0% | -6.4% | -25.0% | - | 9.0% | 9.1% | 19.5% | - |
| FCF growth (YoY) | 90.8% | - | - | - | 64.8% | - | - | - | -1996.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -35.6% | -36.6% | 2.9% | 4.2% | 6.1% | 10.5% | 11.8% | 1.1% | 0.9% | -1.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$3.31B totalUnited States Facilities$3.31B · 100.0%
Product / service
$3.31B totalAcute Inpatient Psychiatric Facilities$1.83B · 55.3%
Specialty Treatment Facilities$567.20M · 17.1%
Comprehensive Treatment Centers$567.18M · 17.1%
Residential Treatment Centers$348.07M · 10.5%
Peer comparison
Same SIC group: Services-Specialty Outpatient Facilities, NEC
Comparing Acadia Healthcare Company against the 5 most active filers in the same SIC group.